Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Impact of incretin-based therapy on skeletal muscle health
Authors:ID Koceva, Andrijana (Author)
ID Janež, Andrej (Author)
ID Jensterle Sever, Mojca (Author)
Files:.pdf PDF - Presentation file, download (816,82 KB)
MD5: 6DBA8C49948CAC48D74A32C495E6062C
 
URL URL - Source URL, visit https://www.mdpi.com/1648-9144/61/9/1691
 
Language:English
Typology:1.02 - Review Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Skeletal muscle is the largest insulin-sensitive tissue in the human body, playing a crucial role in glucose homeostasis, body mobility and overall metabolic health. In obesity and type 2 diabetes (T2D), skeletal muscle undergoes structural, functional, and metabolic alterations, including reduced muscle mass, impaired contractile function, increased myosteatosis, mitochondrial dysfunction, and chronic low-grade inflammation. Incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs are highly effective treatments for T2D and obesity, producing substantial weight loss. While clinical trials suggest proportional loss of fat and lean mass when using incretin-based therapies, emerging preclinical and translational data indicate potential muscle-specific beneficial effects such as attenuation of atrophy, improved myogenesis, enhanced mitochondrial function and reduced myosteatosis. This review comprehensively summarizes the current preclinical and clinical evidence on the impact of incretin-based therapies on skeletal muscle mass, composition, metabolism, and performance, focusing on mechanistic insights from animal models and translational findings from human studies.
Keywords:obesity, incretin-based treatment, liraglutide
Publication status:Published
Publication version:Version of Record
Year of publishing:2025
Number of pages:str. 1-16
Numbering:Vol. 61, iss. 9, [article no.] 1691
PID:20.500.12556/DiRROS-24855 New window
UDC:616.4
ISSN on article:1648-9144
DOI:10.3390/medicina61091691 New window
COBISS.SI-ID:249529603 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 18. 9. 2025;
Publication date in DiRROS:22.12.2025
Views:17
Downloads:9
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Medicina
Publisher:MDPI
ISSN:1648-9144
COBISS.SI-ID:6754623 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:debelost, zdravljenje na osnovi inkretinov, liraglutid


Back